Sarepta Therapeutics Submits Clinical Trial Application for SRP-1005 Huntington's Disease Treatment
核心洞察
Sarepta Therapeutics has submitted a clinical trial application for SRP-1005 (搜索), an investigational siRNA treatment targeting Huntington's disease (搜索).
The company expects to initiate the SRP-1005 (搜索) clinical trial in the second quarter of 2026 as part of its expanding neurodegenerative disease portfolio.
SRP-1005 (搜索) is part of Sarepta's next-generation siRNA platform focused on chronically administered therapies for neurodegenerative and pulmonary diseases.
Sarepta Therapeutics has submitted a clinical trial application for SRP-1005 (搜索), its investigational siRNA treatment for Huntington's disease (搜索), marking a significant expansion of the company's neurodegenerative disease portfolio. The company expects to initiate the SRP-1005 clinical trial in the second quarter of 2026.
Expanding siRNA Platform for Neurological Disorders
SRP-1005 (搜索) represents part of Sarepta's next-generation siRNA platform, which focuses on chronically administered therapies for neurodegenerative and pulmonary diseases. The platform includes investigational treatments targeting multiple rare neurological conditions beyond Huntington's disease (搜索).
The company's siRNA portfolio encompasses treatments for facioscapulohumeral muscular dystrophy (搜索) (FSHD), myotonic dystrophy type 1 (搜索) (DM1), spinocerebellar ataxia type 2 (搜索) (SCA2), and idiopathic pulmonary fibrosis (搜索) (IPF). Sarepta is also pursuing preclinical programs for spinocerebellar ataxia type 1 (SCA1) and spinocerebellar ataxia type 3 (SCA3).
Strategic Collaborations and Pipeline Development
The company maintains an exclusive collaboration with Arrowhead Pharmaceuticals to develop therapies for skeletal muscle diseases, with plans to pursue up to six discovery targets in muscle or central nervous system disorders. This partnership complements Sarepta's internal development efforts across its expanding therapeutic areas.
Company Focus and Mission
Sarepta positions itself as a leader in precision genetic medicine for rare diseases, holding leadership positions in Duchenne muscular dystrophy (搜索) while building a robust portfolio across muscle, central nervous system, and cardiac diseases. The company describes its mission as engineering precision genetic medicine for rare diseases that devastate lives and cut futures short.
Recent Corporate Activity
In parallel with its clinical development progress, Sarepta recently granted equity awards totaling 55,118 restricted stock units to 10 new employees hired in the fourth quarter of 2025. The awards were approved under the company's 2024 Employment Commencement Incentive Plan as material inducements to employment, with vesting occurring over four years in equal annual installments.